Researchers at Princess Margaret Cancer Centre in Toronto are working on a clinical trial to determine whether a blood test can detect very small amounts of cancer that may remain after treatment. The goal is to identify signs of recurrence earlier by finding traces in patients’ blood, rather than relying solely on symptoms or imaging and follow-up appointments.
The outlets describe the work as part of a larger study, with an emphasis on testing the blood test’s ability to identify cancer coming back when disease burden is low. This approach is aimed at helping patients and clinicians monitor for recurrence with greater sensitivity after therapy.
Both sources focus on the same central question—whether a blood-based test can provide meaningful information about whether cancer is returning—while offering limited details on trial size, timeline, or the specific technology used. The reporting presents the blood test as a prospective tool under investigation rather than an available diagnostic or surveillance method today.
